Year None 2026 2025 2024 2023 2022 2021 2020 2019 Sep 04, 2026 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Sep 02, 2026 Arcutis Management to Present at the Morgan Stanley 24th Annual Global Healthcare Conference Aug 07, 2026 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Aug 05, 2026 Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update Jul 16, 2026 Arcutis Expands Board of Directors with Appointment of Chris Peetz Jul 15, 2026 Arcutis to Report Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026 Jul 08, 2026 FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Jul 02, 2026 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jun 30, 2026 Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with C Current page 1 Page 2 Page 3 Page 4 Next page next › Last page last » Displaying 1 - 9 of 33